Tanzania Breast Cancer Therapeutics Market Report 2022 to 2030

Tanzania Breast Cancer Therapeutics Market Analysis

$ 3999

The Tanzania breast cancer therapeutics market is expected to witness growth from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the forecasted year 2022-2030. The main reason for this market growth is the increasing initiatives by the government to build new pharmaceutical plants in order to develop cancer medications. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the major companies in the Tanzania breast cancer therapeutics market are Keko Pharmaceutical, Bristol-Myers Squibb, and Eli Lilly.

ID: IN10TZPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Parul Choudhary

Buy Now

Tanzania Breast Cancer Therapeutics Market Executive Analysis

The Tanzania breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. Tanzania is moving closer to achieving universal healthcare; in 2020-21, $387.9 Mn was allotted by the government for the health sector, of which $155.5 Mn would be used for projects that will enable the government to carry out its plans to improve public health. In 2022-23, the sector will get 40.47 Bn. International donors that contribute up to 40% of the health budget supplement the financing of healthcare. Through USAID and CDC, the US government makes a sizable contribution to initiatives that help the Tanzanian government. Only 32% of Tanzanians had health insurance as of 2019; this indicates the country's low level of health insurance coverage. Only 1% of people have private health insurance.

Breast cancer is a major public health issue in Tanzania, where there are an estimated 10,000 new cases each year. Poor patient outcomes may result from the nation's insufficient capacity for breast cancer diagnosis and treatment. Lack of knowledge about the disease, restricted access to screening and diagnostic facilities, and cultural barriers to seeking care are all factors in Tanzania's high prevalence of breast cancer. Surgery, chemotherapy, radiation, hormone therapy, targeted therapy employing monoclonal antibodies like Bevacizumab and Trastuzumab, as well as palliative and supportive care in advanced cases, are all currently used to treat breast cancer. Due to the advanced stage of presentation, lack of access to diagnostic imaging, and adjuvant therapy, the primary method of treatment for breast cancer in Tanzania is surgery. Therefore, in most situations, mastectomy is the preferred course of action.

Market Dynamics

Market Growth Drivers

Growing government efforts to attract different investors in order to build pharmaceutical factories for the treatment of cancer within Tanzania. The Tanzanian government also intends to create a budget that includes the goods and equipment needed to establish the pharmaceutical plants as well as supplies for health care. These changes would undoubtedly accelerate the Tanzania breast cancer therapeutics market expansion.

Market Restraints

Locally based companies will have to overcome a number of obstacles, including the demand for qualified labor, the accessibility of contemporary technology, and the capacity to scale up to be competitive with suppliers from abroad. These factors will definitely hamper the growth of Tanzania's breast cancer therapeutics market.

Competitive Landscape

Key Players

Bajuta Internation (TZA)
Continental Pharma (TZA)
DKT (TZA)
Kairuki Pharmaceuticals (TZA)
Keko Pharmaceutical (TZA)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Through the National Health Insurance Fund (NHIF), the government of Tanzania pays for breast cancer treatment. A government-funded program called the National Health Insurance Fund (NHIF) offers health insurance to people who cannot afford to pay for certain services out of pocket, such as cancer treatment. However, the NHIF's scope of coverage is narrow, and not every citizen qualifies. However, despite the existence of these policies, there is still a lack of educated healthcare personnel, a lack of facilities and equipment, and insufficient financing, which limits access to breast cancer treatments, including screening, diagnosis, and treatment.

The availability of breast cancer treatment has also been improved in Tanzania by a number of NGOs and international organizations. For instance, the Pink Ribbon Red Ribbon program, a collaboration between the US government and the private sector, aims to enhance the provision of breast and cervical cancer services in Tanzania. The Breast Cancer Association of Tanzania (BRCAT) works to raise awareness about breast cancer and improve access to diagnosis and treatment services.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.